Forensic Analysis · Technology / Software · as of Aug 8, 2026

Agilysys Inc (AGYS)

A forensic read on Agilysys Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

A · High-quality compounder

Forensic grade

Safe

Financial health

15.4

Distress distance

Clean

Earnings quality

Forensic signals

71.8

P / E (ttm)

11.9%

ROE

$3.1B

Market cap

0.00%

Dividend yield

15.9%

Revenue growth

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Agilysys Inc earns an A (High-quality compounder) forensic quality grade, and its balance-sheet distress test reads 15.4, placing it in the Safe zone. 4 forensic signals were flagged in its latest SEC filings, led by share-count dilution.

What the filings flag

+3.1%/yr

FY2023–FY2026

Share-count dilution. Diluted share count changed +9% over the last 3 years to FY2026 (+3.1%/yr). The count is growing: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~3.1% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~9%.

stopped

FY2012→FY2014

Shareholder returns — halted. Capital returns have STOPPED — $13M of buybacks + dividends in FY2012, but ~$0 in FY2014. A halt usually means the company is conserving cash.

14.4%

FY2026

Return on invested capital. Return on invested capital is 14.4% in the latest fiscal year and slipping from 22% — a modest positive spread over its ~10% cost of capital — growth adds value, though not dramatically.

7% of rev

FY2026

Stock-based comp load. Stock-based compensation ran 7% of revenue and 32% of free cash flow in FY2026 — about $0.77 per diluted share. The cost of it is not in the cash flow — no cash left the business — it is in the count, and there it has run at about 3.1% a year and is falling.

Key fundamentals

Latest Revenue$319.3M

Revenue Growth YoY+15.9%

Revenue CAGR (3yr)+17.3%

Net Margin12.1%

Free Cash Flow$68.1M

Return on Equity11.9%

Debt / Equity0.00x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Agilysys Inc's actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Aug 8, 2026. Forensic signals flag probability, not certainty.